FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF CHANGES | S IN BENEFICIA | L OWNERSHIP |
|------------------|------------|----------------|-------------|

| OMB APPROVAL | | | | | | | | |
|-----------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average bur | den | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| | | | | | 01 0 | Jecu | 011 30(11) 0 | ח נווכ | III V C SUITE | iii GC | ilipally A | JE 01 134 | .0 | | | | | | |
|--|--|------------|----------|--|---|---|--------------|--|------------------|-----------|------------------------|---|--|---|---|--|--|---|------------|
| 1. Name and Address of Reporting Person* <u>Cardama Alfonso Quintas</u> | | | | | 2. Issuer Name and Ticker or Trading Symbol TCR2 THERAPEUTICS INC. [TCRR] | | | | | | | | | eck all applic Directo | ationship of Reporting call applicable) Director Officer (give title | | son(s) to Iss 10% Ov Other (s | /ner | |
| (Last) | (F R2 THERA | , | (Middle) | | | 3. Date of Earliest Transaction (Month/Day/Year) 12/15/2022 | | | | | | | | 7 | below) | | below) | posity | |
| 100 BINNEY STREET | | | | | 4 If | 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable | | | | | | | | | | | | | |
| (Street) | IDGE M | ΙA | 02142 | | | | | | | | | Line | X Form filed by One Reporting Person Form filed by More than One Reporting | | | | | | |
| (City) | (S | itate) | (Zip) | | | Person | | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | |
| D | | | Date | 2. Transaction Date (Month/Day/Year) | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | e, Transaction Dispos Code (Instr. 5) | | rities Ac | | (A) or . 3, 4 and | 5. Amour Securitie Beneficia Owned F | s ally ollowing | Form (D) o | : Direct r Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | | Code | v | Amou | nt (| (A) or (D) | | | eported ransaction(s) nstr. 3 and 4) | | | (Instr. 4) |
| Common Stock | | | | | | | | Τ | | | | | 109,459 | | | D | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security Security 2. Conversion Date (Month/Day/Year) (Month/Day/Year) 3A. Deemed Execution Date if any (Month/Day/Year) | | | Date, 1 | Code (Instr. | | n of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | | of Se Unde Deriv | 7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | s Ily | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership t (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exercisa | ıble | Expiration Date | n Title | 1 | Amount or Number of Shares | | | | | |
| Stock Option (Right to Buy) | \$0.97 | 12/15/2022 | | | A | | 70,649 | | (1) | | 12/14/203 | 2 Comr Stoo | | 70,649 | \$0.00 | 70,649 | 9 | D | |
| Restricted Stock Unit (Right to | (2) | 12/15/2022 | | | A | | 11,775 | | (3) | | (3) | Comr | | 11,775 | \$0.00 | 11,775 | 5 | D | |

Explanation of Responses:

- 1. 25% of this option shall vest and become exercisable on the one-year anniversary of the date of grant, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
- 2. Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.
- 3. The restricted stock units will vest 25% on the one-year anniversary of the date of grant, with the remainder vesting in three equal annual installments thereafter.

Remarks:

/s/ Margaret Siegel as Attorney-12/19/2022 in-Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.